Neil Derek Miller studied and trained as an organic chemist in the UK and US before joining GlaxoSmithKline’s R&D organization as a medicinal chemist in 1997. During an 18-year career with the company, he led drug discovery teams that delivered small molecule development candidates, several of which progressed into human clinical trials. In 2007 Neil moved to Singapore, initially as Head of Chemistry at GSK’s new neuroscience R&D site and subsequently as Site Head during which time the unit shifted focus to rare neurodegenerative disorders, including motor neuron disease and Huntington’s disease.
More recently Neil moved into biotech, initially as CSO then CEO at Auspherix Ltd, a company that was developing a novel class of antibiotic. In 2018, Neil co-founded NRG Therapeutics Ltd which is developing novel inhibitors of the mitochondrial permeability transition pore for the treatment of Parkinson’s disease.